The investigational vaccine known as mRNA-1273 protected mice from infection with SARS-CoV-2, the virus that causes COVID-19, according to research published today in Nature. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) and the biotechnology company Moderna, based in Cambridge, Massachusetts, along with collaborators from the University of North Carolina at Chapel Hill, Vanderbilt University Medical Center in Nashville, and the University of Texas at Austin conducted the preclinical research.
- NASA finds Tropical Storm Dolphin going swimmingly
- Regulatory T cells could lead to new immunotherapies aimed at treating multiple sclerosis
- Children with COVID-19 show different immune responses, but better outcomes than adults
- Evaluating impacts of COVID-19 lockdowns on children and young people
- Modeling future COVID-19 cases under a variety of immune responses, and with or without vaccines